UPDATE 1-Amgen must face lawsuit claiming it hid $10.7 billion tax bill Adds details from decision, case citation, byline By Jonathan Stempel NEW YORK, Sept 30 (Reuters) - A federal judge said Amgen AMGN.O must face a proposed class action accusing the drugmaker of waiting too long to tell shareholders it might owe the Internal Revenue Service $10.7 billion for underreporting six years of taxes.

Amgen must face lawsuit claiming it hid $10.7 billion tax bill NEW YORK, Sept 30 (Reuters) - A federal judge said Amgen AMGN.O must face a proposed class action accusing the drugmaker of waiting too long to tell shareholders it might owe the Internal Revenue Service $10.7 billion in taxes and penalties. U.S. District Judge John Cronan in Manhattan ruled on Monday that shareholders plausibly alleged they were misled by Amgen's concealing the true extent of its potential liability, and that the om

RPT-BUZZ-U.S. stocks weekly: Streaking in September Repeats from Friday with no changes to text. Updates chart ** S&P 500 .SPX extends winning streak to three weeks, adds 0.6% amid tame inflation data and China stimulus boost .N ** SPX on pace for monthly gain, take that September! ** Dow .DJI and Nasdaq .IXIC also up three consecutive weeks, though the latter still lined up at the velvet rope ** This as benchmark Treasury yield perks up , but can't hold 3-week highs after PCE ** Most sectors fl

BUZZ-U.S. stocks weekly: Streaking in September ** S&P 500 .SPX extends winning streak to three weeks, adds 0.6% amid tame inflation data and China stimulus boost .N ** SPX on pace for monthly gain, take that September! ** Dow .DJI and Nasdaq .IXIC also up three consecutive weeks, though the latter still lined up at the velvet rope ** This as benchmark Treasury yield perks up , but can't hold 3-week highs after PCE ** Most sectors fleet of foot: Materials sprint to front of the pack, while Energ

US STOCKS-Dow closes at record high as tame inflation report also lifts small caps U.S. PCE stands at 2.2% in Aug Russell 2000 index up 0.67% Bristol-Myers gains after schizophrenia drug approval Costco slips after Q4 revenue misses estimates Indexes: Dow up 0.33%, S&P 500 down 0.13%, Nasdaq down 0.39% Updates with 4:23 pm ET By Echo Wang Sept 27 (Reuters) - T he blue-chip Dow Jones Industrial Average closed at a record high as a subdued inflation report stoked hopes for more Federal Reserve rat

US STOCKS-Dow closes at record high on tame inflation report that also boosts small caps U.S. PCE stands at 2.2% in Aug Russell 2000 index up 1.5% Bristol-Myers gains after schizophrenia drug approval Costco slips after Q4 revenue misses estimates Indexes: Dow up, S&P 500 down, Nasdaq down Updates to 4:00 PM ET By Echo Wang Sept 27 (Reuters) - The blue-chip Dow Jones Industrial Average closed at a record high on Friday as investors welcomed a subdued inflation report that also lifted small -cap

US STOCKS-Dow hits record high on tame inflation report that also boosts small caps U.S. PCE stands at 2.2% in Aug Russell 2000 index up 1.5% Bristol-Myers gains after schizophrenia drug approval Costco slips after Q4 revenue misses estimates Indexes: Dow up 0.45%, S&P 500 down 0.06%, Nasdaq down 0.32% Updates to 2:21 p.m. By Echo Wang Sept 27 (Reuters) - The blue-chip Dow Jones Industrial Average hit a new record high on Friday as investors cheered a tame inflation report that also boosted smal

US STOCKS-S&P 500, Dow close lower as investors await insights on Fed rates, data KB Home falls after Q3 profit misses estimates Apple edges down as data shows China sales drop in Aug Ford, GM slide on Morgan Stanley downgrade Indexes: Dow down 0.70%, S&P 500 down 0.19%, Nasdaq up 0.04% Updates with closing prices By Echo Wang Sept 25 (Reuters) - The Dow Jones Industrial Average and S&P 500 closed lower on Wednesday, pulling back from recent record highs driven by China's sweeping stimulus packa

US STOCKS-S&P 500, Dow end lower as investors await clues on Fed rates, data KB Home falls after Q3 profit misses estimates Apple edges down as data shows China sales drop in Aug Ford, GM slide on Morgan Stanley downgrade Dow weighed down by decline Amgen Updates with closing details By Echo Wang Sept 25 (Reuters) - The Dow Jones Industrial Average and S&P 500 closed lower on Wednesday, retreating from recent record highs fueled by China's sweeping stimulus package , as investors awaited further

BUZZ-Argenx tops BEL 20 index, broker points to positive Vyvgart momentum Updates with U.S. listed shares ** Shares of Belgian biotech company Argenx ARGX.BR closed 3.5 % higher at 485.10 euros, on Wednesday ** Stock topped Belgium's blue-chip BEL 20 index .BFX * * A nalysts at brokerage KBC Securities s ay c ompany's drug Vyvgart is still the top

US STOCKS-S&P 500, Dow retreat as investors await clues on Fed rates, data KB Home falls after Q3 profit misses estimates Apple edges down as data shows China sales drop in Aug Ford, GM slide on Morgan Stanley downgrade Indexes: Dow down 0.63%, S&P 500 down 0.18%, Nasdaq up 0.03% Updates prices, details throughout By Echo Wang Sept 25 (Reuters) - The Dow Jones Industrial Average and S&P 500 edged lower on Wednesday, pulling back from recent record highs spurred by China's sweeping stimulus packa

BUZZ-U.S. STOCKS ON THE MOVE-SLM Corp, Amgen Inc, Cintas Corp Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were mixed on Wednesday, with the S&P 500 hovering near a record high, as investors awaited more indicators on the state of the economy and upcoming interest rate reductions.

US STOCKS-Wall Street mixed as investors await Fed rate clues, data For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. KB Home falls after Q3 profit misses estimates Apple edges down as data shows China sales drop in Aug Ford, GM slide on Morgan Stanley downgrade Indexes: Dow down 0.48%, S&P 500 flat, Nasdaq up 0.26% Updated at 11:42 a.m.

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Constellation Energy Corp CEG.OQ +4.2% Intel Corp INTC.OQ +3.4% NVIDIA Corp NVDA.OQ +2.2% Arm Holdings PLC ARM.OQ +2.2% Advanced Micro Devices Inc AMD.OQ +2.0% Bottom Performers Percent Change Amgen Inc AMGN.OQ -4.7% Diamondback Energy Inc FANG.OQ -2.1% Charter Communications Inc CHTR.OQ -1.9% CoStar Group Inc CSGP.OQ -1.9% Dexcom Inc DXCM.OQ -1.7% The Nasdaq 100 .NDX gained 31.72

BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT S&P 500 .SPX Top Performers Percent Change Vistra Corp VST.N +6.8% Hewlett Packard Enterprise Co HPE.N +4.9% Constellation Energy Corp CEG.OQ +4.4% Intel Corp INTC.OQ +3.2% NVIDIA Corp NVDA.OQ +2.3% Bottom Performers Percent Change General Motors Co GM.N -5.4% Global Payments I

BUZZ-Amgen falls after reporting mixed data on two drugs ** Shares of Amgen AMGN.O fall as much as 4.4% to a near two-month low of $316.22 ** Stock is set for its worst day in nearly two months if losses hold ** Late on Tuesday drugmaker said its drugs Uplizna and rocatinlimab, for a rare muscular disorder and a skin disease, respectively, met the

BUZZ-Street View: Amgen's mixed data on two drugs fans competition concerns ** Amgen's AMGN.O drugs, Uplizna and rocatinlimab, for a rare muscular disorder and for a skin disease, respectively, met the main goals in their late-stage studies ** However, results from its drug rocatinlimab for treating atopic dermatitis or eczema, fell short of its co

BUZZ-ArgenX tops BEL 20 index, broker points to positive Vyvgart momentum ** Shares in Belgian biotech company Argenx ARGX.BR rise 4%, with KBC analysts saying its Vyvgart drug is still the top contender despite positive trial data from a competitor ** Amgen AMGN.O on Tuesday reported favourable phase 3 data for its Uplizna drug in treating rare muscle-weakening disease myasthenia gravis ** "We deem the Uplizna dataset to be strong yet somewhat less compelling than Vyvgart," KBC says ** "Vyvgart

UPDATE 4-Amgen's muscular disorder drug meets main goal in late-stage study Amgen's Uplizna succeeds in study for muscle-weakening Analysts say data from another experimental drug not 'competitive' Shares fall 2% in extended trading on mixed datasets Adds analyst comments in paragraphs 4, 10 and 11, trial data in paragraph 3, 8 and 9, exec comment in paragraph 6 By Bhanvi Satija and Puyaan Singh Sept 24 (Reuters) - Amgen AMGN.O said on Tuesday that its drug helped improve daily activities includ

Amgen's experimental skin disease drug meets main goals in study Sept 24 (Reuters) - Amgen AMGN.O said on Tuesday its experimental drug, rocatinlimab, met the main goals in a late stage study testing it as a treatment for an inflammatory skin condition known as atopic dermatitis. Reporting by Bhanvi Satija and Puyaan Singh in Bengaluru; Editing by